Institutional h-index: 9.56
This is a system proposed by Jorge Hirsch, from the University of California, to measure professional quality. It is an indicator used to evaluate the scientific production of a particulaar researcher. It allows to find the balance between the number of publications and the number of citations. This indicator is also applied to institutions and journals.

Institutional impact factor: 6.87

The Impact Factor measures the frequency with which the average article of a journal is cited in a particular year.
It is the most widely used bibliometric index. It is used to compare journals and assess the relative importance of a specific journal in a given scientific field.
 

Some publications:

• De Miguel-Perez D, Ortega FG, Tejada RG, Martínez-Única A, Peterson CB, Russo A, et al. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. Biomark Res. 15 de noviembre de 2023;11(1):98. https://doi.org/10.1016/j.jtho.2022.02.015
   
• Zhang Y, Wu J, Qin T, Xu Z, Qu S, Pan L, et al. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia. diciembre de 2022;36(12):2875-82. https://doi.org/10.1016/S1470-2045(22)00404-1
   
• Parada-Gereda HM, Tibaduiza AL, Rico-Mendoza A, Molano-Franco D, Nieto VH, Arias-Ortiz WA, et al. Effectiveness of diaphragmatic ultrasound as a predictor of successful weaning from mechanical ventilation: a systematic review and meta-analysis. Crit Care. 5 de mayo de 2023;27(1):174. https://doi.org/10.1158/1078-0432.CCR-22-1912
   
• Lara-Mejía L, Cardona AF, Mas L, Martin C, Samtani S, Corrales L, et al. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology. enero de 2024;19(1):119-29. https://doi.org/10.1186/s13054-023-04430-9
   
• Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. The Lancet Oncology. diciembre de 2023;24(12):1399-410. https://doi.org/10.1016/j.jtho.2023.08.007
   
• Cardona AF, Mejía SA, Viola L, Chamorro DF, Rojas L, Ruíz-Patiño A, et al. Lung Cancer in Colombia. Journal of Thoracic Oncology. agosto de 2022;17(8):953-60. https://doi.org/10.2967/jnumed.122.265340
   
• Perini GF, Idrobo H, Oliver C, Von Glasenapp SA, Castro D, Villela Martinez LM, et al. Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America. Blood. 28 de noviembre de 2023;142(Supplement 1):2422-2422. https://doi.org/10.1182/blood-2023-190477
   
• Kayal G, Barbosa N, Marín CC, Ferrer L, Fragoso-Negrín JA, Grosev D, et al. Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. J Nucl Med. enero de 2024;65(1):125-31. https://doi.org/10.1038/s41375-022-01718-7
   
• Sarria GR, Martinez DA, Del Castillo R, Salgado A, Pinillos L, Felix A, et al. Radiotherapy and cancer status in Latin America: economic analysis of investment opportunities up to 2030. The Lancet Oncology. julio de 2022;23:S5. https://doi.org/10.1186/s40364-023-00544-y
   
• Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G. Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 15 de septiembre de 2023;29(18):3579-91. https://doi.org/10.1016/S1470-2045(23)00469-2

In-house researchers

IGCS 2023 Annual Global Meeting, Seoul, South Korea

• Preoperative brachytherapy for early stage cervical cancer
   

European Lung Cancer Conference 2023 

• Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
• Omeprazole followed by tepotinib in sotorasib resistant-mutant-KRAS G12C non-small cell lung cancer (NSCLC) cell lines and one patient-derived organoid
• Genomic profiling of tissue and blood predicts survival outcomes in patients with resected malignant pleural mesothelioma
   

American Society of Clinical Oncology

• Real-World Characteristics and Outcomes of ERBB2-Mutant Non-Small Cell Lung Cancer in Latin America Patients
• Characteristics of SARSCOV2 infection in vaccinated patients with cancer in one Latin American country: Real world evidence from ACHOCC19-VAC study
   

 
2023 World Conference on Lung Cancer  

• The MET inhibitor tepotinib potentially inhibits KRAS G12C and SHOC2 in KRAS G12C non-small cell lung cancer (NSCLC)
• Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer
• Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
• Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
• Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib

Consorcio Latinoamericano para la Investigación del Cáncer de Pulmón CLICaP

• Radiotherapy in early stage lung cancer
• Andvances management of brain metastases in lung cancer
• Novel biomarkers for NSCLC immunotherapy
• Neo and adjuvant therapy in EGFRm NSCLC
• NSCLC immunotherapy in PD-L1 high expressed
   

 36th Annual Congress - Milan

• Safety of antitumor therapy in critically ill patients
• SAFETY OF ANTITUMORAL THERAPY IN PATIENTS IN INTENSIVE CARE
• Infection by multiresistan gram negative in hematooncological patients. Characterization in Latin America
   

 
ESMO Congress 2023

• Selinexor (XPO1 inhibitor) in Combination with Tepotinib (MET inhibitor) Potentially Inhibits SHOC2 and KRAS G12C in KRAS G12C Mutant Non-Small Cell Lung Cancer

Nanets 2023 Multidisciplinary Net Medical Simposio 

• Thoracic NET
• Panel Discussion: overview of Current Local NET Care Scenario 
• Panel Discussions: perspectives of collaborative work 
• Oligometastatic disease in Neuroendocrine Tumors
• Oligometastatic disease in well-differentiated Neuroendocrine Tumors
• Clinical cases Discussion 
• Metastatic neuroendocrine tumor to the breast
   

ABC Global Alliance

• News from abc 6, er positive her 2 negative
• Member of the consensus panel 
• How to optimally treat patients with advanced/ metastatic breast cancer in visceral crisis

 LALCA -Latin America Conference on Lung Cancer 2023

• Importance of Smoking Cessation in the Treatment of Lung Cancer Patient
• Clinical Research in Lung Cancer: Gaps and Opportunities 
• Incidental Pulmonary Programs as a Complement for Lung Cancer Screening
• Combining Radiation Therapy with Targeted Therapy in Oligometastatic Disease
• Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study
• High Extracellular Vesicle TGF-β & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell Lung Cancer Undergoing Immune-Checkpoint Inhibitors
• Using DNA Next-Generation Sequencing in blood to Guide Therapy for Newly Diagnosed Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
• Molecular Markers for Immunotherapy

What is EVA

Prospective, observational, descriptive study designed to gather and organize the clinical and biological information as well as multiple outcomes of our patient population at the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC). With its information platform, this study will allow for dynamic data capture with logic independence, minimum redundancy and concurrent access by various users, maintaining data integrity and security, in order to evaluate the natural history of several neoplasms diagnosed and treated in a real world setting. This will result in the ability to assess and solve essential cancer-related problems in Colombia. 

How much have we accomplished?

• 47.770 Total variables created
• 2.043 Patients with Informed Consent
• 2.801 Total records delivered for entry into the data capture platform
• 43 Oncologic Disease Forms - FCU
• 6 FAU forms
• 25 Active institutional research studies nested in EVA

How do we do it?

Expected outputs

• Clinical data columns (DCs) for the main oncologic conditions (solid and hematologic tumors) related to complications secondary to the course of the disease and its treatment, associated with oncologic support and quality of life. 
• Databases for clinical-genomic information integration.
• Standardized protocols for the generation of statistical analysis plans (SAPs).
• Guides for selecting study cohorts. 
• Required institutional reporting 
• Integration of the clinical information with prospectively collected biological specimens kept in the CTIC biobank. 
• Outcomes benchmarking with other institutions.  
• Local, regional and international biomedical publications. 
• Books.